Operating performance is highly erratic, with margins swinging from a 20.6% operating margin in 2024Q1 to a deeply negative -71.1% in 2025Q2 due to heavy R&D spending.
| Sales/Revenue | 11.87M | 53.48M | 51.13M | 131.83M | 7.6M | 135K | 0 | 0 |
| Revenue Growth % | -82.16% | 4.58% | -61.21% | 1634.61% | 5529.63% | - | - | - |
| Cost of Goods Sold | 1.64M | 13.38M | 13.24M | 116.72M | 87.85M | 38.77M | 968K | 407K |
| COGS % of Revenue | - | 25.02% | 25.89% | 88.54% | 1155.97% | 28722.22% | - | - |
| Gross Profit | 10.23M | 40.1M | 37.89M | 15.11M | -80.25M | -38.64M | -968K | -407K |
| Gross Margin % | 86.18% | 74.98% | 74.11% | 11.46% | -1055.97% | -28622.22% | - | - |
| Gross Profit Growth % | - | 5.82% | 150.82% | 118.83% | -107.7% | -3891.74% | -137.84% | - |
| Operating Expenses | 85.32M | 133.62M | 154.12M | 34.9M | 28.41M | 15.66M | 24.84M | 12.82M |
| OpEx % of Revenue | - | 249.87% | 301.41% | 26.48% | 373.76% | 11601.48% | - | - |
| Selling, General & Admin | 24.08M | 32.22M | 33.76M | 34.9M | 28.41M | 15.66M | 4.95M | 2.91M |
| SG&A % of Revenue | - | 60.25% | 66.03% | 26.48% | 373.76% | 11601.48% | - | - |
| Research & Development | 65.09M | 116.87M | 133.59M | 120.5M | 91.17M | 41M | 19.89M | 9.91M |
| R&D % of Revenue | - | 218.55% | 261.27% | 91.41% | 1199.62% | 30370.37% | - | - |
| Other Operating Expenses | -2M | -15.47M | -13.24M | -120.5M | -91.17M | -41M | 0 | -1.14M |
| Operating Income | -75.09M | -93.52M | -116.22M | -19.8M | -108.66M | -54.3M | -25.81M | -12.82M |
| Operating Margin % | -632.62% | -174.88% | -227.3% | -15.02% | -1429.74% | -40223.7% | - | - |
| Operating Income Growth % | - | 19.53% | -487.11% | 81.78% | -100.1% | -110.38% | -101.33% | - |
| EBITDA | -72.34M | -91.6M | -114.27M | -17.82M | -107.19M | -53.41M | -24.84M | -12.41M |
| EBITDA Margin % | -609.47% | -171.29% | -223.48% | -13.52% | -1410.38% | -39559.26% | - | - |
| EBITDA Growth % | 19.01% | 19.84% | -541.33% | 83.38% | -100.71% | -114.97% | -100.14% | - |
| D&A (Non-Cash Add-back) | 2.75M | 1.92M | 1.95M | 1.98M | 1.47M | 897K | 968K | 407K |
| EBIT | -74.73M | -92.14M | -116.22M | -19.8M | -108.66M | -54.3M | -26.45M | -13.92M |
| Net Interest Income | 7.01M | 10.39M | 13.33M | 5.63M | 259K | 240K | 0 | 0 |
| Interest Income | 7.01M | 10.39M | 13.33M | 5.63M | 259K | 240K | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 3.93M | 10.27M | 13.04M | 5.9M | 74K | -440K | -644K | -1.43M |
| Pretax Income | -71.16M | -83.25M | -103.18M | -13.9M | -108.59M | -54.74M | -26.45M | -14.25M |
| Pretax Margin % | -599.51% | -155.67% | -201.79% | -10.54% | -1428.76% | -40549.63% | - | - |
| Income Tax | 1.04M | 1.44M | -9.38M | 15.15M | -1.68M | -1.32M | 761K | 35K |
| Effective Tax Rate % | -1.46% | -1.73% | 9.09% | -108.97% | 1.55% | 2.42% | -2.88% | -0.25% |
| Net Income | -72.2M | -84.69M | -93.8M | -29.05M | -106.91M | -53.42M | -27.22M | -14.28M |
| Net Margin % | -608.26% | -158.37% | -183.44% | -22.03% | -1406.68% | -39568.15% | - | - |
| Net Income Growth % | 14.1% | 9.71% | -222.91% | 72.83% | -100.14% | -96.27% | -90.55% | - |
| Net Income (Continuing) | -72.2M | -84.69M | -93.8M | -29.05M | -106.91M | -53.42M | -27.22M | -14.28M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.68 | -2.00 | -2.23 | -0.69 | -2.83 | -1.45 | -0.74 | -0.90 |
| EPS Growth % | 15.5% | 10.31% | -223.19% | 75.62% | -95.17% | -95.95% | 17.78% | - |
| EPS (Basic) | - | -2.00 | -2.23 | -0.69 | -2.83 | -1.45 | -0.74 | -0.90 |
| Diluted Shares Outstanding | 43.05M | 42.41M | 42.09M | 41.92M | 37.82M | 36.9M | 36.67M | 15.79M |
| Basic Shares Outstanding | 42.97M | 42.41M | 42.09M | 41.92M | 37.82M | 36.9M | 36.67M | 15.79M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Clinical milestone dependency
As reported in financial statements, Repare's top-line performance remains highly volatile, characterized by intermittent milestone payments that lack recurring product sales, with revenue fluctuating from $52.4M in 2024Q1 to periods of zero reported revenue, underscoring the inherent unpredictability of a clinical-stage biotechnology business model.
The absence of consistent revenue streams suggests that the company's financial trajectory is entirely tethered to the successful execution of collaboration agreements. Investors should monitor the transition from milestone-dependent income to potential royalty streams, as the current reliance on external partnerships creates significant quarterly variance.
Based on reported figures, the company's cost structure is dominated by research and development expenditures, which consistently dwarf other operating costs and have historically led to significant quarterly operating losses, such as the $37.1M operating loss recorded in 2024Q2 as the pipeline advanced.
The high fixed-cost base reflects the necessary investment in clinical trials and specialized laboratory personnel required to validate the SNIPRx platform. This expense discipline appears focused on pipeline progression rather than near-term profitability, which may necessitate further capital raises to sustain operations.
According to recent SEC filings, the company's operating leverage remains severely constrained by the high cost of clinical development, with operating margins frequently dipping into deeply negative territory, such as the -71.1% margin observed in 2025Q2, indicating a lack of scalable operational efficiency.
The inability to scale operating income relative to gross profit suggests that the company is in a high-burn phase of its lifecycle. Without a commercialized product to offset these fixed R&D costs, the company remains highly sensitive to the timing of clinical data readouts and partnership-related cash inflows.
As indicated by the recent termination of the Roche collaboration for camonsertib, the company faces significant risks regarding the viability of its lead assets, which, when combined with a cash position of $84.7M, warrants further investigation into the potential for dilutive equity financing.
Short-term observers may focus on the company's limited cash runway and the potential for further partnership attrition to undermine the long-term valuation. The reliance on external validation for its platform suggests that any further loss of partner confidence could significantly impair the company's ability to fund its ongoing clinical programs.
Quick answers to the most common questions about buying RPTX stock.
For fiscal year 2024, Repare Therapeutics Inc. (RPTX) reported total revenue of $53.5M.
Repare Therapeutics Inc. (RPTX) reported a net loss of $84.7M for the fiscal year ending 2024.
Repare Therapeutics Inc. (RPTX) reported an operating income of $-93.5M, resulting in an operating profit margin of -174.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Repare Therapeutics Inc. (RPTX) generated $40.1M in gross profit for the year, representing a gross profit margin of 75.0%. This demonstrates the company's core pricing power and production efficiency.